Universität zu Köln

Mulder, Frits I., Candeloro, Matteo, Kamphuisen, Pieter W., Di Nisio, Marcello, Bossuyt, Patrick M., Guman, Noori, Smit, Kirsten, Buller, Harry R., van Es, Nick, Abdel-Razeq, H., Ades, S., Ayappan, S. R., Borchmann, S., Cella, C. A., Fankhauser, C. D., Ferroni, P., Fuentes, H. E., Kruger, S., Lim, S. H., Lubberts, S., Lustig, D. B., Mansfield, A. S., Munoz Martin, A. J., Noble, S., Panizo, E., Papaxoinis, G., Park, K., Patel, J. N., Posch, F., Ramos, J. D., Roselli, M., Santi, R., Sohal, D., Srikanthan, A., Tafur, A. J., Terbuch, A., Thomas, M., Vathiotis, O., Wang, R. and Zahir, M. N. (2019). The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica, 104 (6). S. 1277 - 1288. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Full text not available from this repository.

Abstract

We aimed to evaluate the performance of the Khorana score in predicting venous thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were searched from January 2008 to June 2018 for studies which evaluated the Khorana score. Two authors independently screened studies for eligibility, extracted data, and assessed risk of bias. Additional data on the 6-month incidence of venous thromboembolism were sought by contacting corresponding authors. The incidence in each Khorana score risk group was estimated with random effects meta-analysis. A total of 45 articles and eight abstracts were included, comprising 55 cohorts enrolling 34,555 ambulatory cancer patients. For 27,849 patients (81%), 6-month follow-up data were obtained. Overall, 19% of patients had a Khorana score of 0 points, 64% a score of 1 or 2 points, and 17% a score of 3 or more points. The incidence of venous thromboembolism in the first six months was 5.0% (95% CI: 3.9-6.5) in patients with a low-risk Khorana score (0 points), 6.6% (95% CI: 5.6-7.7) in those with an intermediate-risk Khorana score (1 or 2 points), and 11.0% (95% CI: 8.8-13.8) in those with a high-risk Khorana score (3 points or higher). Of the patients with venous thromboembolism in the first six months, 23.4% (95% CI: 18.4-29.4) had been classified as high risk according to the Khorana score. In conclusion, the Khorana score can be used to select ambulatory cancer patients at high risk of venous thromboembolism for thromboprophylaxis; however, most events occur outside this high-risk group.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Mulder, Frits I. UNSPECIFIED UNSPECIFIED UNSPECIFIED Candeloro, Matteo UNSPECIFIED UNSPECIFIED UNSPECIFIED Kamphuisen, Pieter W. UNSPECIFIED UNSPECIFIED UNSPECIFIED Di Nisio, Marcello UNSPECIFIED UNSPECIFIED UNSPECIFIED Bossuyt, Patrick M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Guman, Noori UNSPECIFIED UNSPECIFIED UNSPECIFIED Smit, Kirsten UNSPECIFIED UNSPECIFIED UNSPECIFIED Buller, Harry R. UNSPECIFIED UNSPECIFIED UNSPECIFIED van Es, Nick UNSPECIFIED UNSPECIFIED UNSPECIFIED Abdel-Razeq, H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ades, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ayappan, S. R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Borchmann, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Cella, C. A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Fankhauser, C. D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ferroni, P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Fuentes, H. E. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kruger, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Lim, S. H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Lubberts, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Lustig, D. B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mansfield, A. S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Munoz Martin, A. J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Noble, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Panizo, E. UNSPECIFIED UNSPECIFIED UNSPECIFIED Papaxoinis, G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Park, K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Patel, J. N. UNSPECIFIED UNSPECIFIED UNSPECIFIED Posch, F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ramos, J. D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Roselli, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Santi, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Sohal, D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Srikanthan, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Tafur, A. J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Terbuch, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Thomas, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Vathiotis, O. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wang, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Zahir, M. N. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-147708
DOI:	10.3324/haematol.2018.209114
Journal or Publication Title:	Haematologica
Volume:	104
Number:	6
Page Range:	S. 1277 - 1288
Date:	2019
Publisher:	FERRATA STORTI FOUNDATION
Place of Publication:	PAVIA
ISSN:	0390-6078
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PATIENTS RECEIVING CHEMOTHERAPY; ADVANCED PANCREATIC-CANCER; MOLECULAR-WEIGHT HEPARIN; RISK PREDICTION; D-DIMER; CLINICAL-SIGNIFICANCE; AMBULATORY PATIENTS; PULMONARY-EMBOLISM; VTE; EVENTS Multiple languages Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/14770